Fecal Incontinence - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fecal Incontinence - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Fecal Incontinence - Pipeline Review, H1 2016', provides an overview of the Fecal Incontinence pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Fecal Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fecal Incontinence and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fecal Incontinence
- The report reviews pipeline therapeutics for Fecal Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Fecal Incontinence therapeutics and enlists all their major and minor projects
- The report assesses Fecal Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Fecal Incontinence

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Fecal Incontinence
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fecal Incontinence pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fecal Incontinence Overview 6
Therapeutics Development 7
Pipeline Products for Fecal Incontinence - Overview 7
Fecal Incontinence - Therapeutics under Development by Companies 8
Fecal Incontinence - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Fecal Incontinence - Products under Development by Companies 11
Fecal Incontinence - Companies Involved in Therapeutics Development 12
Celogos 12
Cook MyoSite Incorporated 13
Innovacell Biotechnologie AG 14
Juventas Therapeutics, Inc. 15
Norgine B.V. 16
RDD Pharma Ltd. 17
Fecal Incontinence - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ICEF-15 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
JVS-100 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
methoxamine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
oxymetazoline hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RCD-2 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Fecal Incontinence - Recent Pipeline Updates 36
Fecal Incontinence - Dormant Projects 40
Fecal Incontinence - Product Development Milestones 41
Featured News & Press Releases 41
Jan 07, 2016: RDD Pharma Announces Additional Positive Results in a Double-Blind Placebo-Controlled Phase 2a Study in Fecal Incontinence 41
Oct 16, 2015: RDD Pharma Announces Positive Results in a Double-Blind Placebo-Controlled Crossover Phase 2a Study in Fecal Incontinence in Patients with Spinal Cord Injury 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Number of Products under Development for Fecal Incontinence, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Fecal Incontinence - Pipeline by Celogos, H1 2016 12
Fecal Incontinence - Pipeline by Cook MyoSite Incorporated, H1 2016 13
Fecal Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2016 14
Fecal Incontinence - Pipeline by Juventas Therapeutics, Inc., H1 2016 15
Fecal Incontinence - Pipeline by Norgine B.V., H1 2016 16
Fecal Incontinence - Pipeline by RDD Pharma Ltd., H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Stage and Target, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Fecal Incontinence Therapeutics - Recent Pipeline Updates, H1 2016 36
Fecal Incontinence - Dormant Projects, H1 2016 40